Currently, gene therapies that use viral vectors are being pursued as additional treatment options for GSD1a patients and have shown promise in correcting hypoglycemia and preventing other metabolic abnormalities in GSD1a animal models (Zingone et al. 2000; Clar et al. 2015; Lee et al. 2015; Kim et al. 2017) and in a clinical trial (Weinstein 2020) (NCT03517085). This evidence concerns the gene G6PC1 and Hypoglycemia.